Prodrugs of proton pump inhibitors

Details Prodrugs of proton pump inhibitors Prodrugs of proton pump inhibitors

1998-08-10

2000-07-25

Rotman, Alan L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514318, 5142352, 544124, 5462737, 546194, A61K 314439, A61K 31445, C07D40112, C07D40114, C07D41312

Patent

active

060937343

ABSTRACT:
Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.

REFERENCES:
patent: 4045563 (1977-08-01), Berntsson et al.
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4686230 (1987-08-01), Rainer et al.
patent: 4758579 (1988-07-01), Kohl et al.
patent: 4965269 (1990-10-01), Brandstrom et al.
patent: 5021433 (1991-06-01), Alminger et al.
patent: 5045552 (1991-09-01), Souda et al.
patent: 5430042 (1995-07-01), Lindberg et al.
patent: 5708017 (1998-01-01), Dave et al.
B.G. Katzung MD,PhD Basic & Clinical Pharmacology, sixth Edition, p. 952, 95.
Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, Design of Prodrugs (Bundgaard, H., ed.) 1985 Elsevier Science Publishers B.V. (Biomedical Division), Chapter 1, H. Bundgaard et al.
Formation of Prodrugs of Amines, Amides, Ureides, and Imides, by H. Bundgaard, Methods in Enzimology, vol. 112, pp. 347-359. (1998).
International Journal of Pharmaceuticals, vol. 22, 1984, pp. 45-56 (Elsevier, H. Bundgaard et al.
International Journal of Pharmaceuticals, vol. 29, 1986, pp. 19-28 (Elsevier), H. Bundgaard et al.
Journal of Medicinal Chemistry, vol. 32, No. 12, Dec. 1989, pp. 2503-2507, H. Bundgaard et al.
Chemical Abstracts, vol. 93, 1980, abstract No. 137935y, Bundgaard et al.
Chemical Abstracts, vol. 95, 1981, abstract No. 138493f, Bundgaard et al.
Chemical Abstracts, vol. 95, 1981, abstract No. 138592n, Bundgaard et al.
Chemical Abstracts, vol. 110, 1989, abstract No. 57664, Alminger et al.
Chemical Abstracts, vol. 115, 1991, abstract No. 64029s, Buur et al.
Chemical Abstracts, vol. 115, 1991, abstract No. 189582y, Hansen et al.
Chemical Abstracts, vol. 117, 1992, abstract No. 14347q, Bundgaard et al.
Chemical Abstracts, vol. 117, 1992, abstract No. 55790x, Jensen et al.
Chemical Abstracts, vol. 123, 1995, abstract No. 17593b, Thomsen et al.

Affiliated with

Also associated with

Rating

Prodrugs of proton pump inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of proton pump inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of proton pump inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1336929